232 related articles for article (PubMed ID: 23817205)
21. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
22. Loss of central auditory processing in a mouse model of Canavan disease.
von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
[TBL] [Abstract][Full Text] [Related]
23. Canavan disease: studies on the knockout mouse.
Matalon R; Michals-Matalon K; Surendran S; Tyring SK
Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
[TBL] [Abstract][Full Text] [Related]
24. Systemic Gene Therapy for Targeting the CNS.
Gombash SE; Foust KD
Methods Mol Biol; 2016; 1382():231-7. PubMed ID: 26611590
[TBL] [Abstract][Full Text] [Related]
25. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse.
Sferra TJ; Qu G; McNeely D; Rennard R; Clark KR; Lo WD; Johnson PR
Hum Gene Ther; 2000 Mar; 11(4):507-19. PubMed ID: 10724030
[TBL] [Abstract][Full Text] [Related]
26. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J
Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282
[TBL] [Abstract][Full Text] [Related]
27. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
28. Aspartoacylase gene knockout in the mouse: impact on reproduction.
Surendran S; Szucs S; Tyring SK; Matalon R
Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
[TBL] [Abstract][Full Text] [Related]
29. Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity.
Xiao Y; Muhuri M; Li S; Qin W; Xu G; Luo L; Li J; Letizia AJ; Wang SK; Chan YK; Wang C; Fuchs SP; Wang D; Su Q; Nahid MA; Church GM; Farzan M; Yang L; Wei Y; Desrosiers RC; Mueller C; Tai PW; Gao G
JCI Insight; 2019 May; 5(13):. PubMed ID: 31112525
[TBL] [Abstract][Full Text] [Related]
30. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10.
Yang B; Li S; Wang H; Guo Y; Gessler DJ; Cao C; Su Q; Kramer J; Zhong L; Ahmed SS; Zhang H; He R; Desrosiers RC; Brown R; Xu Z; Gao G
Mol Ther; 2014 Jul; 22(7):1299-1309. PubMed ID: 24781136
[TBL] [Abstract][Full Text] [Related]
31. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
32. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
Baslow MH; Resnik TR
J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery.
Sénac JS; Chandler RJ; Sysol JR; Li L; Venditti CP
Gene Ther; 2012 Apr; 19(4):385-91. PubMed ID: 21776024
[TBL] [Abstract][Full Text] [Related]
34. White matter disease: Targeted aspartoacylase gene therapy reverts Canavan disease.
Starling S
Nat Rev Neurol; 2018 Jan; 14(1):4. PubMed ID: 29170500
[No Abstract] [Full Text] [Related]
35. Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.
Rafi MA; Rao HZ; Luzi P; Luddi A; Curtis MT; Wenger DA
Mol Genet Metab; 2015 Mar; 114(3):459-66. PubMed ID: 25533112
[TBL] [Abstract][Full Text] [Related]
36. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
37. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
[TBL] [Abstract][Full Text] [Related]
38. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination.
Kirmani BF; Jacobowitz DM; Namboodiri MA
Brain Res Dev Brain Res; 2003 Jan; 140(1):105-15. PubMed ID: 12524181
[TBL] [Abstract][Full Text] [Related]
39. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
[TBL] [Abstract][Full Text] [Related]
40. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system.
Zhang H; Yang B; Mu X; Ahmed SS; Su Q; He R; Wang H; Mueller C; Sena-Esteves M; Brown R; Xu Z; Gao G
Mol Ther; 2011 Aug; 19(8):1440-8. PubMed ID: 21610699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
